{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:10:53Z","timestamp":1765728653766},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T00:00:00Z","timestamp":1515283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000042","name":"Amgen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To examine the dynamics of treatment with 2 bone\u2010targeting agents (BTAs)\u2014denosumab and zoledronic acid\u2014among men with bone metastases from prostate cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using electronic health record data from oncology practices across the US, we identified prostate cancer patients diagnosed with bone metastasis in 2012\/2013 without evidence of BTA use within 6\u00a0months prior to diagnosis. We examined the risk and predictors of BTA initiation, interruption, and re\u2010initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 897 men diagnosed with prostate cancer, the cumulative incidence of BTA initiation after bone metastasis diagnosis was 34% (95% confidence interval [CI], 31\u201337%) at 30\u00a0days, 64% (95% CI, 61\u201368%) at 180\u00a0days, and 88% (95% CI, 85\u201391%) at 2\u00a0years. Denosumab was initiated more frequently than zoledronic acid. Men with diabetes, more bone lesions, history of androgen deprivation therapy, or no hospice enrollment were more likely to initiate treatment. Following initiation, the cumulative incidence of treatment interruption was 17% (95% CI, 14\u201319%) at 60\u00a0days and 70% (95% CI, 66\u201374%) at 2\u00a0years, with interruption more likely among patients receiving emerging therapies for prostate cancer or enrolling in hospice. The cumulative incidence of re\u2010initiation following interruption was 36.3% (95% CI, 32.7\u201340.2%) at 15\u00a0days, 49.8% (95% CI, 45.9\u201354.1%) at 30\u00a0days, and 81.0% (95% CI, 77.5\u201384.7%) at 1\u00a0year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Bone\u2010targeting agent therapy is initiated by the majority of men living with bone metastases following a prostate cancer diagnosis; however, the timing of initiation is highly variable. Once on treatment, gaps or interruptions in therapy are common.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4360","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T04:26:33Z","timestamp":1515558393000},"page":"229-238","source":"Crossref","is-referenced-by-count":8,"title":["Treatment dynamics of bone\u2010targeting agents among men with bone metastases from prostate cancer in the United States"],"prefix":"10.1002","volume":"27","author":[{"given":"Anne M.","family":"Butler","sequence":"first","affiliation":[{"name":"Department of Epidemiology University of North Carolina  Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karynsa","family":"Cetin","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Thousand Oaks and South San Francisco  CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohini K.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Thousand Oaks and South San Francisco  CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Diane Reams","sequence":"additional","affiliation":[{"name":"Department of Epidemiology University of North Carolina  Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Overman","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Outcomes and Policy UNC Eshelman School of Pharmacy  Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung","family":"I. Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of North Carolina  Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford R.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Flatiron Health  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy P.","family":"Abernethy","sequence":"additional","affiliation":[{"name":"Flatiron Health  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Liede","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Thousand Oaks and South San Francisco  CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Alan Brookhart","sequence":"additional","affiliation":[{"name":"Department of Epidemiology University of North Carolina  Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0210"},{"key":"e_1_2_9_4_1","first-page":"87","article-title":"Estimated number of prevalent cases of metastatic bone disease in the US adult population","volume":"4","author":"Li S","year":"2012","journal-title":"Clinical epidemiology"},{"key":"e_1_2_9_5_1","first-page":"335","article-title":"Prevalence of bone metastases and bone\u2010targeting agent use among solid tumor patients in the United States","volume":"7","author":"Hernandez RK","year":"2015","journal-title":"Clinical epidemiology."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0931"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.05.135"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.03.034"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602551"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000108746.69256.45"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi122"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1475-5"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0121-y"},{"key":"e_1_2_9_14_1","unstructured":"Zometa\u00ae (zoledronic acid) [package insert]. Novartis Pharmaceuticals Corporation East Hanover NJ; 2016.https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/Zometa.pdf. Accessed June 16 2016."},{"key":"e_1_2_9_15_1","unstructured":"XGEVA\u00ae (denosumab) [package insert]. Amgen Inc. Thousand Oaks CA; 2016.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125320s094lbl.pdf. Accessed June 16 2016."},{"key":"e_1_2_9_16_1","unstructured":"National Comprehensive Cancer Network (NCCN) Foundation.NCCN Guidelines for Patients.\u00ae Prostate Cancer Version 1.2015.https:\/\/www.nccn.org\/patients\/guidelines\/prostate\/. Accessed March 20 2015."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.05.005"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338810"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.117"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv222"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8404"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000358258"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2011.03.015"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.05.026"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23775"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19425"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2251-y"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S92209"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_9_30_1","unstructured":"R Core Team(2013).R: a language and environment for statistical computing. R foundation for statistical computing Vienna Austria. ISBN 3\u2010900051\u201007\u20100 URLhttp%3A%2F%2Fwww.r-project.org\/."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2741-0"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2258"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0377"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.024224"},{"key":"e_1_2_9_35_1","unstructured":"Prolia\u00ae (denosumab) [package insert]. Amgen Inc. Thousand Oaks CA; 2011.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125320s5s6lbl.pdf. Accessed September 5 2017."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4360","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T16:10:20Z","timestamp":1694275820000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,7]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/pds.4360"],"URL":"https:\/\/doi.org\/10.1002\/pds.4360","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,7]]}}}